SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest long-term Week 40 Phase 3 data, which demonstrates deepening clinical efficacy and reinforces the company's best-in-class potential for treating Hidradenitis Suppurativa. The community is actively discussing the drug's regulatory pathway toward a BLA submission and the potential for a strategic buyout, while simultaneously debating market maker activity and recent analyst upgrades that have significantly raised price targets.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following a series of significant Department of Defense and defense-contractor awards, which have sparked intense community debate over the company's long-term production scalability and balance sheet health. While bulls point to these mission-critical manufacturing contracts as validation of the company's technology, short-sellers and skeptical investors remain focused on ongoing cash burn concerns and the potential for future equity dilution.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is generating significant market interest following a series of operational and financial milestones, including strong cash margins and the securing of long-term offtake agreements. Investors are actively debating the company's growth thesis and debt reduction progress, while recent momentum has been bolstered by increased lithium demand visibility and broader sector excitement regarding energy storage and electrification.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant retail interest and community debate ahead of upcoming earnings and guidance updates, with bulls citing the company's long-term pivot toward the QNX operating system for software-defined vehicles and robotics as a major catalyst. While some community members voice skepticism regarding historical revenue growth and management's execution, many long-term holders are actively accumulating shares, viewing current levels as a deep-value opportunity based on the company's backlog and strategic partnerships.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Alcoa is trending as investors weigh the impact of new U.S. metal tariffs, creating significant debate over whether the policy provides domestic support or threatens profit margins through higher import costs. Community discourse is heavily focused on the stock's volatility and its long-term potential as a key player in critical infrastructure and data center construction.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following positive trial data from its TETON-1 study, which demonstrated that nebulized Tyvaso significantly preserves lung function in patients with idiopathic pulmonary fibrosis. The community is actively discussing the potential for a major label expansion that could triple the addressable market for the therapy, leading to multiple analyst price target increases as the company prepares for an FDA submission.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing significant downward pressure following the release of phase 3 clinical trial data for its thyroid eye disease drug, elegrobart, which failed to demonstrate the level of efficacy compared to IV-based treatments that investors had hoped for. While management emphasizes the drug's safety profile and ongoing clinical progress, market participants are actively debating the competitive threat from established standards of care and potential future rivals, leading to increased volatility and a sharp decline in share price.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air Group is currently at the center of investor focus following a Q1 guidance revision that widened projected losses, driven by fuel cost headwinds and operational challenges in Hawaii and Mexico. Despite the near-term volatility, the community is actively debating the stock's valuation, highlighting its strategic positioning, long-term growth prospects, and recent heavy institutional accumulation as indicators that the shares may be undervalued.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing intense downward pressure driven by a combination of geopolitical instability in the Middle East and market FUD surrounding Google's new memory-compression technology. While the community remains deeply divided between those viewing the current valuation as a generational buying opportunity and those fearing further technical breakdowns, investors are closely watching key support levels as they navigate the disconnect between the company's strong fundamentals and persistent institutional selling.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing significant momentum and investor interest following a successfully upsized financing round and positive clinical updates for its lead CAR-T candidate, NXC-201. The community is actively discussing the stock's potential for a valuation re-rate, focusing on the company's clear regulatory path, the involvement of major institutional biotech funds, and the anticipation of upcoming enrollment milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MRNA $pfe $jnj $bntx Does anyone know how the Eastern vaccines from Russia and China stand up to the Western vaccines? How come we never hear anything about their vaccines, maybe they are better? Maybe we should at least try them?

Mykah Hicks

erik

StockTwits Web

Moderna Inc

Johnson & Johnson

Pfizer Inc

BioNTech SE - ADR

 Does anyone know how the Eastern vaccines from Russia and China stand up to the Western vaccines? How come we never hear anything about their vaccines, maybe they are better? Maybe we should at least try them?

Hawaiian Electric Industries, Inc.

AMC Entertainment Holdings

Pinterest Inc

SoFi Technologies Inc

Beyond Meat Inc

Draganfly Inc

Rocket Lab USA Inc

guilefort

@guile Here is a Chilenean study on the Sinovac vaccine: 65.9%  efficiency prior to Delta. Other studies have yielded 51%

https://www.nejm.org/doi/full/10.1056/NEJMoa2107715

Sputnik is technically similar to the JNJ vaccine, and should also have a similar efficacy (app. 80%). Problem there is a/o, that they tend to fail on their delivery contracts (e.g. Argentina, and a number of other Latin American countries).

Our apologies. An error occurred while setting your user cookie. Please set your browser to accept cookies to continue. NEJM.org uses cookies to improve performance by remembering your session ID when you navigate from page to page. This cookie stores just a session ID; no other information is captured.

Nejm

 Here is a Chilenean study on the Sinovac vaccine: 65.9%  efficiency prior to Delta. Other studies have yielded 51%





Sputnik is technically similar to the JNJ vaccine, and should also have a similar efficacy (app. 80%). Problem there is a/o, that they tend to fail on their delivery contracts (e.g. Argentina, and a number of other Latin American countries).

Glaxosmithkline plc - ADR

CureVac N.V.

August Starke

@Augusto14 I wonder why American vaccines aren&#39;t marketed to South America

 I wonder why American vaccines aren't marketed to South America

@guile They are. See the extract from my Comirnaty ($BNTX / $PFE) 2021 order tally below. $MRNA also has a handful of deals in Latin America.

2022 boosters are a/o under negotiation with Costa Rica, Panama, Peru and Uruguay. PFE will do fill&amp;finish in Brazil from next year on.

💎💎💎💎 (Stock Gold Medalist🥇)

Bjorn Mjölgard

 They are. See the extract from my Comirnaty (

 also has a handful of deals in Latin America.

2022 boosters are a/o under negotiation with Costa Rica, Panama, Peru and Uruguay. PFE will do fill&finish in Brazil from next year on.